Special Issue

Recent Developments in Cancer Biomarkers for Diagnosis and Prognosis

Message from the Guest Editor

The biological molecules reflecting the state of initiation and progression in cancer are deemed important biomarkers. These molecules can be measured in tissues, plasma serum saliva, and other biological fluids. Cancer biomarkers are useful not only for early detection but also for monitoring disease progression and treatments. Measuring one biomarker may not be sufficient for all cancer types, and some cancers require a group of biomarkers for accurate diagnosis. These biomarkers could be a combination of tissue and secretory factors. This Special Issue welcomes research articles addressing recent research on experimental, pre-clinical, and clinical cancer biomarkers for diagnosis and prognosis, with a special focus on approaches for discovering novel cancer biomarkers. Biomarkers can include proteins, nucleic acids, metabolites, and more.

Guest Editor

Dr. Raghu Sinha

Department of Molecular and Precision Medicine, Penn State College of Medicine, Penn State Cancer Institute, Penn State Centre for Research on Tobacco and Health, Hershey, PA, USA

Deadline for manuscript submissions

30 September 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/207524

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

